U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research | CDER
  5. Office of Neuroscience - Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP)
  1. Center for Drug Evaluation and Research | CDER

Office of Neuroscience - Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP)


The Office of New Drugs is undergoing a reorganization. This site will be updated in the near future.  Please check back often.  For more information, please visit: Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality. Until this page is updated, please use the current contact information presented on this page or contact druginfo@fda.hhs.gov if you have additional questions.

The Division of Anesthesia, Addiction Medicine and Pain Medicine (DAAP) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products for the treatment of Acute Pain, e.g. Surgical and procedural pain, pain due to trauma/injury, pain due to acute inflammatory processes; Chronic pain, e.g.: cancer pain, neuropathic pain, fibromyalgia, osteoarthritis pain, low back pain and addiction, e.g.: nicotine, alcohol, stimulants, opioids. DAAP also regulates the drug product classes that are used in surgical, procedural or ICU settings to provide patient comfort and/or ease of treatment, e.g.: general anesthetics, local anesthetics, dental anesthetics, topical anesthetics, neuromuscular-blocking agents and neuromuscular-blocker reversal agents.

Division Director: Sharon Hertz, M.D.
Deputy Directors: Joshua Lloyd, M.D. and Rigoberto Roca, M.D.
Deputy Director for Safety: Judith Racoosin, M.D., M.P.H
Associate Director for Opioids: Megan Moncur, M.S.
Associate Director for Special Projects: Allison Lin, Ph.D., Pharm.D.
Safety Regulatory Project Manager: Mark Liberatore, Pharm.D.
Regulatory Operations Chiefs, Project Management Staff:  Parinda Jani and Matthew Sullivan

The Division of Anesthesiology, Addiction Medicine, and Pain Medicine regulates and reviews Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for prescription drugs and biologics intended for the prevention, treatment, or diagnosis of conditions including:

  • Acute Pain, e.g.:
    • Surgical and procedural pain
    • Pain due to trauma/injury
    • Pain due to acute inflammatory processes
  • Chronic pain, e.g.:
    • Cancer pain
    • Neuropathic pain
    • Fibromyalgia
    • Osteoarthritis Pain
    • Low back pain
  • Addiction, e.g.:
    • Nicotine
    • Alcohol
    • Stimulants
    • Opioids

DAAP also regulates the drug product classes that are used in surgical, procedural or ICU settings to provide patient comfort and/or ease of treatment, e.g.:

  • General anesthetics
  • Local anesthetics
  • Dental anesthetics
  • Topical anesthetics
  • Neuromuscular-blocking agents and neuromuscular-blocker reversal agents

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP)
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2280
Fax: (301) 796-9723

Resources For You